CIK 0002012593
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 880724208
- Phone
- +1 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- Open-market buys, last 90 days
- $22,023,904
- in 7 filings
- Open-market sales, last 90 days
- $4,490,340
- in 8 filings, $4.5M under 10b5-1 plans
Net +$17,533,565. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-19 | Bredt David Chief Scientific Officer | Option exercise 10b5-1 | +6,000 | $1.80 | $11K | 393,075 |
| 2026-02-19 | Bredt David Chief Scientific Officer | Option exercise · Stock Options (Right to Buy) 10b5-1 | −6,000 | 88,080 | ||
| 2026-02-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −900 | $28.02 | $25K | 394,675 |
| 2026-02-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −5,400 | $28.95 | $156K | 389,275 |
| 2026-02-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −2,200 | $29.59 | $65K | 387,075 |
| 2026-02-02 | Bredt David Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +103,000 | 103,000 | ||
| 2026-01-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −8,300 | $26.83 | $223K | 395,775 |
| 2026-01-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −200 | $27.40 | $5K | 395,575 |
| 2025-12-31 | Bredt David Chief Scientific Officer | Grant or award | −18,000 | 410,642 | ||
| 2025-12-31 | Bredt David Chief Scientific Officer | Sale | −6,567 | $30.05 | $197K | 404,075 |
| 2025-12-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −7,704 | $29.95 | $231K | 393,438 |
| 2025-12-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −796 | $30.68 | $24K | 392,642 |
| 2025-11-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −3,156 | $24.84 | $78K | 406,486 |
| 2025-11-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −5,344 | $25.39 | $136K | 401,142 |
| 2025-10-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −7,418 | $25.73 | $191K | 410,724 |
| 2025-10-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −1,082 | $26.16 | $28K | 409,642 |
| 2025-09-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −5,098 | $23.88 | $122K | 421,544 |
| 2025-09-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −3,402 | $24.66 | $84K | 418,142 |
| 2025-08-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −8,300 | $14.98 | $124K | 426,842 |
| 2025-08-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −200 | $15.79 | $3K | 426,642 |
Page 1 of 2 · 27 trades